Skip to main content
Premium Trial:

Request an Annual Quote

Horizon Discovery, Silicos Ink Screening Pact

NEW YORK (GenomeWeb News) – Horizon Discovery has signed a commercial agreement with the drug discovery company Silicos for testing compounds on human isogenic cell lines based on specific genotypes, Horizon said on its website Monday.

The agreement covers the testing of Silicos compounds using Horizon's X-MAN mutant and normal cell line technology to enable the drug maker to gather information about its compounds, including data about selectivity and mode-of-action, using model in vitro systems. Such genotype-specific compound studies could help pharmaceutical and biotech companies advance their aims in personalized medicine, Horizon said.

Horizon Chairman Darrin Disley said in a statement that Silicos' multi-target screening approach is "should lead to the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases including cancer."

Financial terms of the agreement were not released.